<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079391</url>
  </required_header>
  <id_info>
    <org_study_id>040112</org_study_id>
    <secondary_id>04-H-0112</secondary_id>
    <nct_id>NCT00079391</nct_id>
    <nct_alias>NCT00076778</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies</brief_title>
  <official_title>Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Peri-transplant Cyclosporine on Chimerism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of stem cell transplantation in which
      the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added
      back. Certain patients with bone marrow malignancies undergo transplantation of donated stem
      cells to generate new and normally functioning bone marrow. However, T-cells from the donor
      may see the patient's cells as foreign and mount an immune response to reject them, causing
      what is called &quot;graft-versus-host-disease&quot; (GVHD). Therefore, in this protocol, T-cells are
      removed from the donor cells to prevent this complication. However, because T-cells are
      important in fighting viral infections as well as any remaining malignant cells (called
      graft-versus-leukemia effect), the donor T-cells are given to the patient (added back) at a
      later time after the transplant when they can provide needed immunity with less risk of
      causing GVHD.

      Patients between 10 and 55 years of age with acute or chronic leukemia, myelodysplastic
      syndrome, or myeloproliferative syndrome may be eligible for this study. Prospective
      participants and their donors are screened with a medical history and physical examination,
      blood tests (including a test to match for genetic compatibility), breathing tests, chest and
      sinus x-rays, and tests of heart function. They also undergo a bone marrow biopsy and
      aspiration. For this procedure, done under local anesthetic, about a tablespoon of bone
      marrow is withdrawn through a needle inserted into the hipbone.

      They undergo apheresis to collect lymphocytes for research studies. This procedure involves
      collecting blood through a needle in the arm, similar to donating a unit of blood. The
      lymphocytes are then separated and removed by a cell separator machine, and the rest of the
      blood is returned through a needle in the other arm.

      Before treatment begins, patients have a central intravenous line (flexible plastic tube)
      placed in a vein in the chest. This line remains in place during the stem cell transplant and
      recovery period for drawing and transfusing blood, giving medications, and infusing the
      donated cells. Preparation for the transfusion includes high-dose radiation and chemotherapy.
      Patients undergo total body irradiation in 8 doses given in two 30-minute sessions a day for
      4 days. Eight days before the transplant, they begin taking fludarabine, and 3 days before
      the procedure they start cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bone marrow stem cell transplant studies carried out by the National Heart Lung &amp; Blood
      Institute (NHLBI) Bone Marrow Transplantation (BMT) Unit have focused on approaches to
      optimize the stem cell and lymphocyte dose in order to improve transplant survival and
      increase the graft-versus-leukemia effect. The aim is to create the transplant conditions
      that permit rapid donor immune recovery without causing graft-versus-host disease (GVHD) by
      using reduced post-transplant immunosuppression in conjunction with a transplant depleted of
      T cells to a fixed low dose, below the threshold known to be associated with GVHD.

      We have found that the outcome from transplant is improved by controlling the stem cell
      (CD34+ cell) and T lymphocyte (CD3+ cell) dose. We use the &quot;Nexell Isolex 300i&quot; system to
      obtain high CD34+ doses depleted of lymphocytes to a fixed CD3+ T cell dose of 2 x 104/kg.
      The use of the cell separator and the monoclonal antibodies is covered by an Investigational
      Device Exemption. A persisting problem with these T cell depleted transplants has been the
      slow acquisition of full donor T cell engraftment (T cell chimerism). Two previous protocols
      have failed to increase the speed of donor T cell chimerism. Patients with mixed
      donor-recipient T cell populations are known to be at higher risk for late graft rejection
      and leukemic relapse after transplant. Therefore, the achievement of full donor chimerism
      remains an important therapeutic goal. In this study we will test whether cyclosporine given
      between day -6 and +21 after transplant can significantly improve day 30 T cell chimerism
      (the principle end-point). The study also will measure the incidence of acute and chronic
      GVHD, day 100 transplant related mortality, cytomegalovirus reactivation, relapse, and
      disease-free survival with appropriate safety stopping rules.

      This protocol follows closely previous studies in this series. Three additional modifications
      will be made however: 1) The first T cell add-back will be delayed until day 60 (instead of
      day 45) so as to continue to allow a 45 day period without cyclosporine immunosuppression. 2)
      No day 100 T cell add-back will be given. (In previous studies many patients have, for
      protocol-defined reasons, not received the second transfusion and there is no evidence that
      it is required). 3) Patients with high-risk leukemias with a high relapse probability will
      receive an additional chemotherapy agent prior to transplant using etoposide (VP16) 60mg/kg
      to improve the chance of remaining in remission.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>The proportion of patients who develop full donor CD3+ lymphocyte chimerism by day 30.
Full chimerism is defined as &gt;95% donor alleles by molecular profiling (Short Tandem Repeat analysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at 5 years post transplant</time_frame>
    <description>Kaplan Meier estimate of survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non Relapse Mortality.</measure>
    <time_frame>at 5 years post transplant</time_frame>
    <description>Non relapse mortality: death without relapse
Kaplan Meier estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Relapse</measure>
    <time_frame>at 5 years post transplant</time_frame>
    <description>Kaplan Meier-estimate of relapse incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)</measure>
    <time_frame>First 60 days</time_frame>
    <description>Incidence of acute Graft versus host disease (GVHD) grades II-IV (before day 60 T cell add back)
Modified &quot;Glucksberg&quot; grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute GVHD Overall</measure>
    <time_frame>First 100 days</time_frame>
    <description>Incidence of acute GVHD grades II-IV (before and after T cell add back) Modified Glucksberg grading</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Bone Marrow Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>allogeneic hematopoietic SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>allogeneic hematopoietic stem cell transplantation (SCT) using Nexell Isolex system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.</description>
    <arm_group_label>allogeneic hematopoietic SCT</arm_group_label>
    <other_name>Peripheral Blood Stem Cell Transplant</other_name>
    <other_name>HSCT</other_name>
    <other_name>BMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        RECIPIENT:

          -  1. Ages 10-55 years inclusive (but less than 56)

          -  2. Chronic myelogenous leukemia (CML) in chronic phase

          -  3. Acute lymphoblastic leukemia (ALL) categories

               1. Adults in first remission with high-risk features

               2. All second or subsequent remissions, primary induction failure, partially
                  responding or untreated relapse

          -  4. Acute myelogenous leukemia (AML)

               1. AML in first remission Except AML with good risk karyotypes

               2. All AML in second or subsequent remission, primary induction failure and
                  resistant relapse

          -  5. Myelodysplastic syndromes categories

               1. refractory anemia with transfusion dependence

               2. refractory anemia with excess of blasts

               3. transformation to acute leukemia, chronic myelomonocytic leukemia

          -  6. Myeloproliferative disorders in transformation to acute leukemia

          -  7. Chronic lymphocytic leukemia refractory to fludarabine treatment and with bulky
             progressive disease or with thrombocytopenia (less than or equal to 100,000 /micro L)
             or anemia (less than or equal to 10g/dl) not due to recent chemotherapy

          -  8. Non-Hodgkin's lymphoma including Mantle cell lymphoma relapsing or refractory to
             current chemotherapy and monoclonal antibody treatment and unsuitable for autologous
             stem cell transplantation

          -  9. No major organ dysfunction precluding transplantation

          -  10. Diffusion capacity of lung for carbon monoxide (DLCO) greater than or equal to 60%
             predicted

          -  11. Left ventricular ejection fraction: greater than or equal to 40%

          -  12. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1

          -  13. Able to give informed consent

          -  14. Negative pregnancy test for women of childbearing age

        INCLUSION CRITERIA:

        DONOR

          -  1. Human leukocyte antigen (HLA) 6/6 identical family donor

          -  2. Weight greater than or equal to 18 kg

          -  3. Age greater than or equal to 2 or less than or equal to 80 years old

          -  4. Fit to receive granulocyte colony -stimulating factor(G-CSF) and give peripheral
             blood stem cells (normal blood count, normotensive, no history of stroke)

        EXCLUSION CRITERIA:

        RECIPIENT

          -  1. Patient pregnant

          -  2. Age less than 10 years and 56 years or more

          -  3. Patients with CML in chronic phase who are 41 years or over in whom imatinib
             mesylate (STI-571)is the treatment of choice

          -  4. ECOG performance status of 2 or more

          -  5. Severe psychiatric illness

          -  6. Major anticipated illness or organ failure incompatible with survival from BMT

          -  7. DLCO less than 60% predicted

          -  8. Left ventricular ejection fraction: less than 40%

          -  9. Serum creatinine greater than 3mg/dl

          -  10. Serum bilirubin greater than 4 mg/dl

          -  11. HIV positive 12. Debilitation or age making the risk of intensive myeloablative
             therapy unacceptable

        EXCLUSION CRITERIA:

        DONOR

          -  1. Pregnant or lactating

          -  2. Donor unfit to receive G-CSF and undergo apheresis

          -  3. HIV positive

          -  4. Weight less than 18 kg

          -  5. Age less than 2 or greater than 80 years

          -  6. Severe psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minocher Battiwalla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIH National Heart, Lung and Blood Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2004-H-0112.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <results_reference>
    <citation>Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant. 2006 Dec;12(12):1318-25.</citation>
    <PMID>17162214</PMID>
  </results_reference>
  <results_reference>
    <citation>Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, Solomon SR, Barrett AJ. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol. 2005 Sep;130(5):733-9.</citation>
    <PMID>16115130</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <results_first_submitted>April 20, 2011</results_first_submitted>
  <results_first_submitted_qc>April 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2012</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Heart, Lung, and Blood Institute (NHLBI)</investigator_affiliation>
    <investigator_full_name>Minoo Battiwalla, M.D.</investigator_full_name>
    <investigator_title>Staff Clinician</investigator_title>
  </responsible_party>
  <keyword>Chronic Myelogenous Leukemia (CML)</keyword>
  <keyword>Acute Lymphoblastic Leukemia (ALL)</keyword>
  <keyword>Acute Myelogenous Leukemia (AML)</keyword>
  <keyword>Chronic Lymphocytic Leukemia (CLL)</keyword>
  <keyword>Myelodysplastic Syndromes (MDS)</keyword>
  <keyword>Peripheral Blood Stem Cells</keyword>
  <keyword>Graft-Versus Leukemia/Myeloma</keyword>
  <keyword>Graft-Versus-Host Disease (GVHD)</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Myeloproliferative Syndrome</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bone Marrow Transplantation Using &quot;Nexell Isolex 300i&quot;</title>
          <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. cluster of differentiation 34 (CD34) selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50">1 of these withdrew after consent.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bone Marrow Transplantation Using Nexell Isolex 300i</title>
          <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30</title>
        <description>The proportion of patients who develop full donor CD3+ lymphocyte chimerism by day 30.
Full chimerism is defined as &gt;95% donor alleles by molecular profiling (Short Tandem Repeat analysis).</description>
        <time_frame>Day 30</time_frame>
        <population>Per protocol; only patients who survived to day 30 and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Transplantation Using Nexell Isolex 300i</title>
            <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30</title>
          <description>The proportion of patients who develop full donor CD3+ lymphocyte chimerism by day 30.
Full chimerism is defined as &gt;95% donor alleles by molecular profiling (Short Tandem Repeat analysis).</description>
          <population>Per protocol; only patients who survived to day 30 and were evaluable.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Kaplan Meier estimate of survival</description>
        <time_frame>at 5 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Transplantation Using Nexell Isolex 300i</title>
            <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Kaplan Meier estimate of survival</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non Relapse Mortality.</title>
        <description>Non relapse mortality: death without relapse
Kaplan Meier estimate</description>
        <time_frame>at 5 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Transplantation Using Nexell Isolex 300i</title>
            <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Non Relapse Mortality.</title>
          <description>Non relapse mortality: death without relapse
Kaplan Meier estimate</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Relapse</title>
        <description>Kaplan Meier-estimate of relapse incidence</description>
        <time_frame>at 5 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Transplantation Using &quot;Nexell Isolex 300i&quot;</title>
            <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. Cluster of differentiation 34 (CD34) selection and T cell depletion using &quot;Isolex 300i&quot; immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Relapse</title>
          <description>Kaplan Meier-estimate of relapse incidence</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)</title>
        <description>Incidence of acute Graft versus host disease (GVHD) grades II-IV (before day 60 T cell add back)
Modified &quot;Glucksberg&quot; grading</description>
        <time_frame>First 60 days</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Transplantation Using &quot;Nexell Isolex 300i&quot;</title>
            <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)</title>
          <description>Incidence of acute Graft versus host disease (GVHD) grades II-IV (before day 60 T cell add back)
Modified &quot;Glucksberg&quot; grading</description>
          <population>Per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute GVHD Overall</title>
        <description>Incidence of acute GVHD grades II-IV (before and after T cell add back) Modified Glucksberg grading</description>
        <time_frame>First 100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Transplantation Using Nexell Isolex 300i</title>
            <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GVHD Overall</title>
          <description>Incidence of acute GVHD grades II-IV (before and after T cell add back) Modified Glucksberg grading</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bone Marrow Transplantation Using Nexell Isolex 300i</title>
          <description>Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant Related Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Life threatening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute GVHD before day 60</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Chronic GVHD</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Disease Relapse</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Acute GVHD after day 60</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus disease</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Minocher Battiwalla</name_or_title>
      <organization>NIH National Heart, Lung and Blood Institute</organization>
      <phone>301-402-4170</phone>
      <email>battiwalla@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

